# A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants

> **NCT04503603** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 12 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Lanadelumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04503603
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-10
- **Primary completion:** 2020-12-23
- **Final completion:** 2020-12-23
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04503603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04503603, "A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04503603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*